CG Oncology Future Growth
Future criteria checks 2/6
CG Oncology is forecast to grow earnings and revenue by 33.6% and 71.9% per annum respectively. EPS is expected to grow by 42.7% per annum. Return on equity is forecast to be -23% in 3 years.
Key information
33.6%
Earnings growth rate
42.7%
EPS growth rate
| Biotechs earnings growth | 27.6% |
| Revenue growth rate | 71.9% |
| Future return on equity | -23.0% |
| Analyst coverage | Low |
| Last updated | 11 Dec 2024 |
Recent future growth updates
Recent updates
CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene
Dec 13Companies Like CG Oncology (NASDAQ:CGON) Are In A Position To Invest In Growth
Oct 04
CG Oncology: Promising Data, But Looks Expensive
Aug 26CG Oncology, Inc. (NASDAQ:CGON) Shares Could Be 42% Below Their Intrinsic Value Estimate
Jul 25CG Oncology Bringing Undervalued Innovation To Bladder Cancer
Jul 09CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value
May 06Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 109 | -89 | -121 | -21 | 5 |
| 12/31/2025 | 4 | -116 | -118 | -113 | 5 |
| 12/31/2024 | 1 | -79 | -94 | -88 | 5 |
| 9/30/2024 | 1 | -79 | -73 | -73 | N/A |
| 3/31/2024 | 1 | -72 | -64 | -64 | N/A |
| 12/31/2023 | 0 | -68 | -46 | -46 | N/A |
| 9/30/2023 | 0 | -57 | -38 | -38 | N/A |
| 12/31/2022 | 0 | -44 | -30 | -30 | N/A |
| 12/31/2021 | 10 | -18 | -14 | -14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CGON is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CGON is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CGON is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CGON's revenue (71.9% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: CGON's revenue (71.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CGON is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 11:53 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CG Oncology, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charlie Yang | BofA Global Research |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Corinne Johnson | Goldman Sachs |